Partner Organizations
December 2024: Entered into a strategic partnership with China National Nuclear Corporation (CNNC) to jointly advance equity investment, nuclide supply, and the development of the radiopharmaceutical industry chain;
May 2025: Established a tripartite joint laboratory with CNNC and Southern Hospital.
Investor relations
In March 2024, collaborated with BeiGene to jointly advance the clinical study of FC084 in combination with tislelizumab.
December 2024: Entered into collaboration with Xiuzheng Pharmaceutical to jointly develop a drug-device combination for BNCT.
May 2025: Signed a technical service contract with Xiuzheng Pharmaceutical with a total value of approximately 20 million yuan.
